-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明,無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
Trade Alert: The Chairman Of Zhongzhi Pharmaceutical Holdings Limited (HKG:3737), Zhi Tian Lai, Has Just Spent CN¥3.4m Buying A Few More Shares
Trade Alert: The Chairman Of Zhongzhi Pharmaceutical Holdings Limited (HKG:3737), Zhi Tian Lai, Has Just Spent CN¥3.4m Buying A Few More Shares
Potential Zhongzhi Pharmaceutical Holdings Limited (HKG:3737) shareholders may wish to note that the Chairman, Zhi Tian Lai, recently bought HK$3.4m worth of stock, paying HK$0.95 for each share. However, it only increased shareholding by a small percentage, and it wasn't a huge purchase by absolute value, either.
Check out our latest analysis for Zhongzhi Pharmaceutical Holdings
Zhongzhi Pharmaceutical Holdings Insider Transactions Over The Last Year
Notably, that recent purchase by Zhi Tian Lai is the biggest insider purchase of Zhongzhi Pharmaceutical Holdings shares that we've seen in the last year. That means that an insider was happy to buy shares at around the current price of HK$1.02. While their view may have changed since the purchase was made, this does at least suggest they have had confidence in the company's future. We do always like to see insider buying, but it is worth noting if those purchases were made at well below today's share price, as the discount to value may have narrowed with the rising price. The good news for Zhongzhi Pharmaceutical Holdings share holders is that insiders were buying at near the current price.
In the last twelve months Zhongzhi Pharmaceutical Holdings insiders were buying shares, but not selling. The chart below shows insider transactions (by companies and individuals) over the last year. If you click on the chart, you can see all the individual transactions, including the share price, individual, and the date!
SEHK:3737 Insider Trading Volume May 2nd 2022There are plenty of other companies that have insiders buying up shares. You probably do not want to miss this free list of growing companies that insiders are buying.
Insider Ownership of Zhongzhi Pharmaceutical Holdings
For a common shareholder, it is worth checking how many shares are held by company insiders. We usually like to see fairly high levels of insider ownership. Zhongzhi Pharmaceutical Holdings insiders own about HK$538m worth of shares (which is 61% of the company). This kind of significant ownership by insiders does generally increase the chance that the company is run in the interest of all shareholders.
So What Do The Zhongzhi Pharmaceutical Holdings Insider Transactions Indicate?
It is good to see recent purchasing. We also take confidence from the longer term picture of insider transactions. Along with the high insider ownership, this analysis suggests that insiders are quite bullish about Zhongzhi Pharmaceutical Holdings. Looks promising! While we like knowing what's going on with the insider's ownership and transactions, we make sure to also consider what risks are facing a stock before making any investment decision. You'd be interested to know, that we found 4 warning signs for Zhongzhi Pharmaceutical Holdings and we suggest you have a look.
If you would prefer to check out another company -- one with potentially superior financials -- then do not miss this free list of interesting companies, that have HIGH return on equity and low debt.
For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions, but not derivative transactions.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Potential Zhongzhi Pharmaceutical Holdings Limited (HKG:3737) shareholders may wish to note that the Chairman, Zhi Tian Lai, recently bought HK$3.4m worth of stock, paying HK$0.95 for each share. However, it only increased shareholding by a small percentage, and it wasn't a huge purchase by absolute value, either.
電勢中智醫藥控股有限公司(HKG:3737)股東不妨留意,主席智天來最近買入價值340萬港元的股票,每股作價0.95港元。然而,它只增加了一小部分股權,從絕對值來看,這也不是一筆大筆收購。
Check out our latest analysis for Zhongzhi Pharmaceutical Holdings
查看我們對中智醫藥控股的最新分析
Zhongzhi Pharmaceutical Holdings Insider Transactions Over The Last Year
中智醫藥控股去年的內幕交易
Notably, that recent purchase by Zhi Tian Lai is the biggest insider purchase of Zhongzhi Pharmaceutical Holdings shares that we've seen in the last year. That means that an insider was happy to buy shares at around the current price of HK$1.02. While their view may have changed since the purchase was made, this does at least suggest they have had confidence in the company's future. We do always like to see insider buying, but it is worth noting if those purchases were made at well below today's share price, as the discount to value may have narrowed with the rising price. The good news for Zhongzhi Pharmaceutical Holdings share holders is that insiders were buying at near the current price.
值得注意的是,智天來最近的收購是我們去年看到的最大規模的中智醫藥控股股票內幕收購。這意味着,一位內部人士樂於以目前1.02港元的價格買入股票。儘管他們的觀點可能在收購後發生了變化,但這至少表明他們對公司的未來充滿信心。我們總是喜歡看到內幕收購,但值得注意的是,這些收購是在遠低於今天股價的情況下進行的,因為相對於價值的折扣可能隨着股價的上漲而收窄。對於中智醫藥控股的股東來説,好消息是,內部人士以接近當前價格的價格買入。
In the last twelve months Zhongzhi Pharmaceutical Holdings insiders were buying shares, but not selling. The chart below shows insider transactions (by companies and individuals) over the last year. If you click on the chart, you can see all the individual transactions, including the share price, individual, and the date!
在過去的12個月裏,中智醫藥控股的內部人士在買入股票,但沒有賣出。下面的圖表顯示了過去一年的內幕交易(按公司和個人)。如果你點擊圖表,你可以看到所有的個人交易,包括股票價格、個人和日期!
There are plenty of other companies that have insiders buying up shares. You probably do not want to miss this free list of growing companies that insiders are buying.
還有很多其他公司讓內部人士買進股票。你很可能會這麼做不想懷念這一切嗎?免費內部人士正在收購的成長型公司名單。
Insider Ownership of Zhongzhi Pharmaceutical Holdings
中智醫藥控股的內部人所有權
For a common shareholder, it is worth checking how many shares are held by company insiders. We usually like to see fairly high levels of insider ownership. Zhongzhi Pharmaceutical Holdings insiders own about HK$538m worth of shares (which is 61% of the company). This kind of significant ownership by insiders does generally increase the chance that the company is run in the interest of all shareholders.
對於一個普通股股東來説,公司內部人士持有多少股份值得一查。我們通常希望看到相當高水平的內部人士持股。中智醫藥控股的內部人士持有價值約5.38億港元的股份(佔公司股份的61%)。這種由內部人士持有的重大所有權通常確實增加了公司以所有股東的利益運營的機會。
So What Do The Zhongzhi Pharmaceutical Holdings Insider Transactions Indicate?
那麼,中智醫藥控股的內幕交易意味着什麼呢?
It is good to see recent purchasing. We also take confidence from the longer term picture of insider transactions. Along with the high insider ownership, this analysis suggests that insiders are quite bullish about Zhongzhi Pharmaceutical Holdings. Looks promising! While we like knowing what's going on with the insider's ownership and transactions, we make sure to also consider what risks are facing a stock before making any investment decision. You'd be interested to know, that we found 4 warning signs for Zhongzhi Pharmaceutical Holdings and we suggest you have a look.
很高興看到最近的採購。我們還從更長期的內幕交易圖景中獲得信心。除了較高的內部人持股比例,這一分析表明,內部人士相當看好中智醫藥控股。看起來很有希望!雖然我們喜歡知道內部人士的所有權和交易情況,但在做出任何投資決定之前,我們也要確保考慮到一隻股票面臨的風險。你會有興趣知道,我們發現了中智醫藥控股的4個警告標誌,我們建議你看看。
If you would prefer to check out another company -- one with potentially superior financials -- then do not miss this free list of interesting companies, that have HIGH return on equity and low debt.
如果你更願意看看另一家公司--一家財務狀況可能更好的公司--那麼不要錯過這一點免費列出了一些有趣的公司,這些公司擁有高股本回報率和低債務。
For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions, but not derivative transactions.
就本文而言,內部人是指向相關監管機構報告其交易的個人。我們目前負責公開市場交易和私人處置,但不包括衍生品交易。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
對這篇文章有什麼反饋嗎?擔心內容嗎?保持聯繫直接與我們聯繫。或者,也可以給編輯組發電子郵件,地址是implywallst.com。
這篇由《華爾街日報》撰寫的文章本質上是籠統的。我們僅使用不偏不倚的方法提供基於歷史數據和分析師預測的評論,我們的文章並不打算作為財務建議。它不構成買賣任何股票的建議,也沒有考慮你的目標或你的財務狀況。我們的目標是為您帶來由基本面數據驅動的長期重點分析。請注意,我們的分析可能不會將最新的對價格敏感的公司公告或定性材料考慮在內。簡單地説,華爾街在提到的任何股票中都沒有頭寸。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧